Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Revive Therapeutics Ltd
C.RVV
Alternate Symbol(s):
RVVTF
Healthcare
Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is...
evaluating a point-of-care in vitro diagnostic device that aids in the detection of post COVID-19 conditions or Long COVID. It also advancing the development of Psilocybin-based therapeutics through various programs. The Company's subsidiaries include Revive Therapeutics Inc. (Ontario), Revive Diagnostics Inc., and Psilocin Pharma Corp. (Ontario).
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Company Website
Add To Watchlist
Bullboard (CSE:RVV)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(5)
•••
cool888
X
View Profile
View Bullboard History
Post by
cool888
on Jan 13, 2023 7:14pm
Pfizer vaccine led to a higher risk of ischemic stroke !
#Bucillamine https://www.politico.com/news/2023/01/13/cdc-fda-pfizer-bivalent-vaccine-possible-strokes-00077933
(5)
•••
cool888
X
View Profile
View Bullboard History
Post by
cool888
on Jan 13, 2023 7:07pm
New COVID subvariant is now dominant across the U.S !
#Bucillamine https://www.marketwatch.com/story/new-covid-subvariant-is-now-dominant-across-the-u-s-accounting-for-43-of-all-new-cases-in-latest-week-cdc-says-11673624990
GameSquare Holdings Reports Record 2024 Third Quarter Results
posted Nov 15, 2024 9:00am by
GameSquare Holdings Inc.
-
|
Justin Kenna, CEO of GameSquare, stated, "GameSquare delivered strong third quarter financial results that were in line with our pre-announcement, and reflect the strategies underway to drive organic sales growth, complete the integration of our recent acquisitions, and build a profitable organization. On a sequential basis, I am encouraged by the ...read more
(618)
•••
CrazyProphet
X
View Profile
View Bullboard History
Post by
CrazyProphet
on Jan 13, 2023 1:49pm
This thing wants to break
higher lets get on with it retail investors before you miss the boat
(5)
•••
cool888
X
View Profile
View Bullboard History
Post by
cool888
on Jan 12, 2023 9:56pm
Always live life to the fullest! Life is so unpredictable !
#Bucillamine
(19)
•••
newonthestreet
X
View Profile
View Bullboard History
Comment by
newonthestreet
on Jan 12, 2023 5:03pm
RE:Facebook posts
I'm so pis$ed with this whole fiasco!!
(5)
•••
1ottrunner
X
View Profile
View Bullboard History
Post by
1ottrunner
on Jan 12, 2023 1:54pm
Facebook posts
Some cheerleading over on the fb. How great it is that the offering is fulling subscribed. So, you realized that YOU as an investor have paid to give others the benefit of free shares? That's
...more
(7)
•••
90guppy
X
View Profile
View Bullboard History
Comment by
90guppy
on Jan 12, 2023 1:34pm
RE:Update !
COOL aka DA FO-OL, very predictable your sound board stupid post. Call out mgt to not fcking f>ck up the type c meeting. that is all u need to fcking post. dont be a pos!
(5)
•••
cool888
X
View Profile
View Bullboard History
Post by
cool888
on Jan 12, 2023 1:31pm
Update !
# Bucillamine https://ca.finance.yahoo.com/news/revive-therapeutics-submit-updated-briefing-181500705.html
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jan 12, 2023 1:15pm
New Press Release - Revive Therapeutics To Submit Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
TORONTO, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announces it will submit an...
read article.
(7)
•••
90guppy
X
View Profile
View Bullboard History
Comment by
90guppy
on Jan 12, 2023 9:07am
RE:Revive Therapeutics Ltd. Closes $4.3 Million Offering
COOL aka da- FO-OL, just fcking call out mgt not to mess up the type c meet, that is all you have to do rather be a useless POS.
(5)
•••
cool888
X
View Profile
View Bullboard History
Post by
cool888
on Jan 12, 2023 6:48am
Revive Therapeutics Ltd. Closes $4.3 Million Offering
#Bucillamine https://ca.finance.yahoo.com/news/revive-therapeutics-ltd-closes-4-110000951.html
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jan 12, 2023 6:00am
New Press Release - Revive Therapeutics Ltd. Closes $4.3 Million Offering
TORONTO, Jan. 12, 2023 (GLOBE NEWSWIRE) -- REVIVE THERAPEUTICS LTD. (CSE: RVV; OTCQB: RVVTF; FRANKFURT:31R) (“Revive” or the “Company”) is pleased to announce that it has completed the closing of its previously announced private placement (the “Offering”) by issuing a total of 28,676,064 units...
read article.
(7)
•••
90guppy
X
View Profile
View Bullboard History
Comment by
90guppy
on Jan 10, 2023 3:42pm
RE:$RVV -First-in-kind psychedelic trials treat opioid and meth
FO-OL- aka COOL call out RVV mgt to not fyck up the type c meet, this is all in the hands of mgt, everything hangs on them.
(618)
•••
CrazyProphet
X
View Profile
View Bullboard History
Post by
CrazyProphet
on Jan 10, 2023 11:56am
Looks to be under
Accumulation
(5)
•••
cool888
X
View Profile
View Bullboard History
Post by
cool888
on Jan 09, 2023 8:52pm
$RVV -First-in-kind psychedelic trials treat opioid and meth
#psychedelic https://news.wisc.edu/two-first-in-kind-clinical-trials-explore-psilocybin-for-substance-misuse/ Study sponsored by Revive. See “Funded Clinical Studies”. https://pharmacy.wisc
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Geodrill Generates Revenue of $34.1M, a 13% Increase Compared to $30.3M for Q3-2023
This $10M Deal Could Reshape the Future of Global Creator Platforms
Coppernico Drills 19 Meters of 0.50% Copper in First 5 Holes and Applies for Additional Permits
New Gold and Copper Hotspot Identified – What’s Next for This Serbian Project?
Major Funding Secured! Company Closes First Round of Private Placement
Have you held units of a TD mutual fund (other than through a discount broker)? Learn more.